Literature DB >> 11881746

Engineered modeling and the secrets of Parkinson's disease.

M Vila1, D C Wu, S Przedborski.   

Abstract

The development of new methods for manipulating the animal genome by transgenic and gene-targeting technologies provides a unique means of studying the most intimate aspects of countless human diseases, including Parkinson's disease (PD). In this review, the contribution of such engineered models to our current understanding of the pathophysiology, etiology and pathogenesis of PD will be discussed.

Entities:  

Mesh:

Year:  2001        PMID: 11881746     DOI: 10.1016/s0166-2236(00)01984-6

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  3 in total

1.  Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.

Authors:  Yoshihisa Kitamura; Takashi Taniguchi; Shun Shimohama; Akinori Akaike; Yasuyuki Nomura
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

2.  Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

Authors:  William Lin; Un Jung Kang
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

3.  Protein expression in the striatum and cortex regions of the brain for a mouse model of Huntington's disease.

Authors:  Xiaoyun Liu; Benjamin R Miller; George V Rebec; David E Clemmer
Journal:  J Proteome Res       Date:  2007-07-11       Impact factor: 4.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.